Abstract
Polycystic ovary syndrome (PCOS) is a heterogeneous syndrome of reproductive and metabolic derangements. The combination of anovulation and hyperandrogenism signifies the classic form of PCOS which displays the adverse metabolic phenotype of the syndrome. This phenotype includes visceral obesity and insulin resistance as well as a constellation of other traditional cardiovascular risk factors, mainly low grade inflammation, disturbances of glucose metabolism and dyslipidemia. The resultant increased risk for cardiovascular disease may affect not only obese but also lean women with classic PCOS. The mechanisms underlying the increased cardiovascular risk in the context of PCOS may include not only metabolic aberrations, but also hormonal factors, in particular hyperandrogenemia. However, the consequences in terms of CV morbidity remain questionable due to the difficulties in conducting long-term, prospective studies aimed at identifying potential late-arriving clinical outcomes.
Keywords: PCOS, hyperandrogenism, cardiovascular, metabolism, inflammation.
Current Pharmaceutical Design
Title:Structural, Biochemical and Non-Traditional Cardiovascular Risk Markers in PCOS
Volume: 19 Issue: 32
Author(s): Charikleia Christakou and Evanthia Diamanti-Kandarakis
Affiliation:
Keywords: PCOS, hyperandrogenism, cardiovascular, metabolism, inflammation.
Abstract: Polycystic ovary syndrome (PCOS) is a heterogeneous syndrome of reproductive and metabolic derangements. The combination of anovulation and hyperandrogenism signifies the classic form of PCOS which displays the adverse metabolic phenotype of the syndrome. This phenotype includes visceral obesity and insulin resistance as well as a constellation of other traditional cardiovascular risk factors, mainly low grade inflammation, disturbances of glucose metabolism and dyslipidemia. The resultant increased risk for cardiovascular disease may affect not only obese but also lean women with classic PCOS. The mechanisms underlying the increased cardiovascular risk in the context of PCOS may include not only metabolic aberrations, but also hormonal factors, in particular hyperandrogenemia. However, the consequences in terms of CV morbidity remain questionable due to the difficulties in conducting long-term, prospective studies aimed at identifying potential late-arriving clinical outcomes.
Export Options
About this article
Cite this article as:
Christakou Charikleia and Diamanti-Kandarakis Evanthia, Structural, Biochemical and Non-Traditional Cardiovascular Risk Markers in PCOS, Current Pharmaceutical Design 2013; 19 (32) . https://dx.doi.org/10.2174/1381612811319320011
DOI https://dx.doi.org/10.2174/1381612811319320011 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Use of Plant Sterol and Stanol Fortified Foods in Clinical Practice
Current Medicinal Chemistry A Direct Correlation between Red Blood Cell Indices and Cognitive Impairment After Aneurysmal Subarachnoid Hemorrhage (aSAH)
Current Neurovascular Research Safety Considerations in the Use of Ketorolac for Postoperative Pain
Current Drug Safety Small-Molecules Targeting Kinases Involved in Pulmonary Hypertension: a Patent Review (2010-2015)
Current Medicinal Chemistry Lipoproteins in Atherosclerosis Process
Current Medicinal Chemistry New Approaches to Raising the HDL Cholesterol Level
Mini-Reviews in Medicinal Chemistry Lipoprotein (a) Evolution: Possible Benefits and Harm. Genetic and Non-Genetic Factors Influencing its Plasma Levels
Current Medicinal Chemistry Anti-inflammatory and Antioxidant Agents from Salvia Genus (Lamiaceae): An Assessment of the Current State of Knowledge
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Effects of Different Types of Physical Exercise on the Perceived Quality of Life in Active Elderly
CNS & Neurological Disorders - Drug Targets Leptin Transport Across the Blood-Brain Barrier: Implications for the Cause and Treatment of Obesity
Current Pharmaceutical Design The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus Receiving Lipid-Lowering Drugs: A Sub-Analysis of the CEPHEUS Findings
Current Vascular Pharmacology Vitamin D status in coronary artery disease: association with IL-35 and TGF-β1 and disease severity
Endocrine, Metabolic & Immune Disorders - Drug Targets Premature Ovarian Insufficiency and Long-Term Health Consequences
Current Vascular Pharmacology Diabetic Retinopathy, Superoxide Damage and Antioxidants
Current Pharmaceutical Biotechnology Adiponectin and Cardiovascular Disease: Mechanisms and New Therapeutic Approaches
Current Medicinal Chemistry Blockade of Renin Angiotensin System in Heart Failure Post-Myocardial Infarction: What is the Best Therapy?
Recent Patents on Cardiovascular Drug Discovery Indolo[3,2-b]quinolines: Synthesis, Biological Evaluation and Structure Activity-Relationships
Mini-Reviews in Medicinal Chemistry CARING (CAncer Risk and INsulin analoGues): The Association of Diabetes Mellitus and Cancer Risk with Focus on Possible Determinants - A Systematic Review and a Meta-Analysis
Current Drug Safety Anti-Apoptotic Effect of Human Telomerase Reverse Transcriptase on Endothelial Cells under Oxidative Stress, Independent of Telomere Elongation and Telomerase Activity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Syntheses of 2,3-Diarylated 2H-Benzo[e][1,2]Thiazine 1,1-Dioxides and their 3,4-Dihydro Derivatives, and Assessment of their Inhibitory Activity Against MCF-7 Breast Cancer Cells
Medicinal Chemistry